专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2015051326A8 POLYMER ENGINEERED REGENERATING BIOSCAVENGERS 审中-公开
标题翻译：聚合物工程重新生产BIOS加工商
公开(公告)号：WO2015051326A8
公开(公告)日：2016-03-17
申请号：PCT/US2014059171
申请日：2014-10-03
申请人： UNIV CARNEGIE MELLON
发明人： RUSSELL ALAN J , MURATA HIRONOBU , CUMMINGS CHAD , KOEPSEL RICHARD R
IPC分类号： C12N11/08 , A62D3/02 , A62D3/30
CPC分类号： C12N9/96 , A61K38/465 , A61K38/4826 , A61K47/48176 , A61K47/58 , C12N9/16 , C12N9/6427 , C12Y301/01007 , C12Y304/21001
摘要： Embodiments of the invention provide at least one polymer covalently conjugated to an esterase. The at least one polymer includes a plurality of oxime functional groups.
摘要翻译：本发明的实施方案提供至少一种与酯酶共价缀合的聚合物。所述至少一种聚合物包括多个肟官能团。

2. 发明申请

WO2013020366A1 乙酰胆碱酯酶作为核酸酶的应用审中-公开
公开(公告)号：WO2013020366A1
公开(公告)日：2013-02-14
申请号：PCT/CN2012/001056
申请日：2012-08-08
申请人：中国科学院上海生命科学研究院 , 张学军 , 谢敬 , 杜爱英 , 郭凯杰 , 吴军
发明人：张学军 , 谢敬 , 杜爱英 , 郭凯杰 , 吴军
IPC分类号： A61K38/46 , C12N15/55 , C12N15/63 , C12N9/16 , C12Q1/46 , A61P35/00 , A61P43/00
CPC分类号： C12N9/18 , A61K38/465 , C07K2319/00 , C07K2319/09 , C12N15/1137 , C12N15/85 , C12Q1/46 , C12Y301/01007 , G01N33/573 , G01N2333/918 , G01N2500/02
摘要：本发明提供了乙酰胆碱酯酶（Ache）作为核酸酶的应用。提供了Ache在调节核酸稳定性和调节细胞凋亡方面的用途，以及基于此的一系列制剂，包括促进或抑制细胞凋亡的试剂，抑制肿瘤的试剂，保护核酸不受损伤的试剂。

3. 发明申请

WO2006083945A8 RNAI-MEDIATED INHIBITION OF OCULAR TARGETS 审中-公开
标题翻译： RNAI介导的OCARAR目标的抑制作用
公开(公告)号：WO2006083945A8
公开(公告)日：2007-10-11
申请号：PCT/US2006003515
申请日：2006-02-01
申请人： ALCON INC , SHEPARD ALLAN R , CHATTERTON JON E , CLARK ABBOT F , WAX MARTIN B
发明人： SHEPARD ALLAN R , CHATTERTON JON E , CLARK ABBOT F , WAX MARTIN B
IPC分类号： A61K31/713 , C12N15/113
CPC分类号： C12N15/1137 , C12N15/1138 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12Y301/01007 , C12Y306/03009 , C12Y402/01001
摘要： RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; ß1- and ß2 adrenergic receptors; acetylcholinesterase; Na + /K + -ATPase; and Na-K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.
摘要翻译：提供RNA干扰用于抑制眼高血压靶mRNA表达，以降低开角型青光眼或高眼压患者眼内压升高。眼睛高血压指标包括碳酸酐酶II，IV和XII; β1-和β2肾上腺素能受体; 乙酰胆碱酯酶; 娜^{+ / K ^{+ -ATP酶; 和Na-K-2Cl共转运蛋白。通过施用本发明的干扰RNA来治疗眼高血压。}}

4. 发明申请

WO00031290A1 METHODS AND COMPOSITIONS FOR PAIN MANAGEMENT 审中-公开
标题翻译：疼痛管理方法与组成
公开(公告)号：WO00031290A1
公开(公告)日：2000-06-02
申请号：PCT/US1999/027582
申请日：1999-11-22
IPC分类号： A61K38/46 , C12Q1/46 , G01N33/52 , G01N33/94
CPC分类号： G01N33/523 , A61K38/465 , C12Q1/46 , C12Q2334/30 , C12Q2334/70 , C12Y301/01007 , G01N33/9406 , G01N33/944 , G01N2800/52 , Y10S435/975
摘要： The present invention provides novel methods and diagnostic kits for the objective measurement of the severity of pain or stress being experienced by a patient with a disorder, diagnosis and treatment for patients suffering from painful disorders, and monitoring the effectiveness of different pain-treatment protocols. Pain-measuring methods comprise collecting a sample from a patient and determining the presence of a pain-associated marker in the sample. Methods for alleviating pain comprise administrating a dose of a therapeutically effective amount of a composition to the patient wherein the dose is determined by the presence of a pain-associated marker in a biological sample obtained from the patient. Compositions for alleviating pain comprise substances that are pain-associated markers or agents that interfere with pain-associated markers, and block or modulate the progression of pain perceived by the patient.
摘要翻译：本发明提供了用于客观测量患有疼痛病症的患者的病症，诊断和治疗的患者经历的疼痛或压力的严重程度以及监测不同疼痛治疗方案的有效性的新型方法和诊断试剂盒。疼痛测量方法包括从患者收集样品并确定样品中疼痛相关标志物的存在。减轻疼痛的方法包括向患者施用治疗有效量的组合物的剂量，其中通过在从患者获得的生物样品中存在疼痛相关标志物来确定剂量。用于缓解疼痛的组合物包括与疼痛相关的标志物或干扰疼痛相关标志物的试剂以及阻断或调节患者感觉到的疼痛进展的物质。

5. 发明申请

WO1998026062A2 SYNTHETIC ANTISENSE OLIGODEOXYNUCLEOTIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM 审中-公开
标题翻译：合成抗体寡糖氧化酶和含有它们的药物组合物
公开(公告)号：WO1998026062A2
公开(公告)日：1998-06-18
申请号：PCT/US1997023598
申请日：1997-12-12
申请人： YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM , KOHN, Kenneth, I. , SOREQ, Hermona , SEIDMAN, Shlomo , ECKSTEIN, Fritz , FRIEDMAN, Alon , KAUFER, Daniela
发明人： YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM , KOHN, Kenneth, I.
IPC分类号： C12N15/00
CPC分类号： C12Y301/01007 , A01K2217/05 , A61K38/00 , C12N15/1137 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/53 , C12N2310/3521
摘要： A synthetic nuclease resistant antisense oligodeoxynucleotide (AS-ODN) capable of selectively modulating human acetylcholinesterase (AChE) production and a pharmaceutical or medical composition comprising at least one AD-ODN as an active ingredient. In an embodiment the AS-ODN can be selected from 5'ACGCTTTCTTGAGGC 3' (SEQ ID NO.1), 5'GGCACCCTGGGCAGC 3' (SEQ ID NO.2); 5'CCACGTCCTCCTGCACCGTC 3' (SEQ ID NO.6); 5'ATGAACTCGATCTCGTAGCC 3' (SEQ ID NO.7); 5'GCCAGAGGAGGAGGAGAAGG 3' (SEQ ID NO.4); 5'TAGCGTCTACCACCCCTGAC 3' (SEQ ID NO.5), 5'TCTGTGTTATAGCCCAGCCC 3' (SEQ ID NO.17); and 5'GGCCTGTAACAGTTTATTT 3' (SEQ ID NO.18). A nuclease resistant antisense targeted against the splice junction in the AChEmRNA post splice message is disclosed. In an embodiment, a nuclease resistant AS-ODN targeted against the E4-E6 junction in the E1-E4-E6 splice variant AChEmRNA is disclosed as being highly specific for the muscle and central nervous system splice variant of AChE. The synthetic nuclease resistant AS-ODNs are capable of selectively modulating human AChE production in the central nervous system or capable of selectively reducing human AChE deposition in the neuromuscular junction. The present invention also provides a method to restore balanced cholinergic signaling in the brain and spinal cord or reduce AChE in the neuromuscular junction in patients in need of such treatment comprising administering to a patient in need of such treatment a therapeutically effective amount of at least one of the synthetic nuclease resistant AS-ODN capable of selectively modulating human AChE production.
摘要翻译：能够选择性调节人乙酰胆碱酯酶（AChE）生产的合成核酸酶抗性反义寡脱氧核苷酸（AS-ODN）和包含至少一种AD-ODN作为活性成分的药物或医药组合物。在一个实施方案中，AS-ODN可以选自5'ACGCTTTCTTGAGGC 3'（SEQ ID NO.1），5'GGCACCCTGGGCAGC 3'（SEQ ID NO.2）; 5'CCACGTCCTCCTGCACCGTC 3'（SEQ ID NO.6）; 5'ATGAACTCGATCTCGTAGCC 3'（SEQ ID NO.7）; 5'GCCAGAGGAGGAGGAGAAGG 3'（SEQ ID NO.4）; 5'TAGCGTCTACCACCCCTGAC 3'（SEQ ID NO.5），5'TCTGTGTTATAGCCCAGCCC 3'（SEQ ID NO.17）; 和5'GGCCTGTAACAGTTTATTT 3'（SEQ ID NO.18）。公开了针对针对AChEmRNA后剪接消息中的剪接连接的核酸酶抗性反义。在一个实施方案中，公开了针对E1-E4-E6剪接变体AChEmRNA中的E4-E6连接的核酸酶抗性AS-ODN作为AChE的肌肉和中枢神经系统剪接变体的高度特异性。合成的核酸酶抗性AS-ODNs能够选择性调节中枢神经系统中的人AChE产生或能够选择性地降低神经肌肉接头中的人类AChE沉积。本发明还提供一种在需要这种治疗的患者中恢复脑和脊髓中的平衡胆碱能信号传导或减少神经肌肉接头中的AChE的方法，包括向需要这种治疗的患者施用治疗有效量的至少一种的能够选择性调节人AChE生产的合成核酸酶抗性AS-ODN。

6. 发明申请

WO2006083945A3 RNAI-MEDIATED INHIBITION OF OCULAR TARGETS 审中-公开
标题翻译： RNAi介导的眼球抑制作用
公开(公告)号：WO2006083945A3
公开(公告)日：2007-08-23
申请号：PCT/US2006003515
申请日：2006-02-01
申请人： ALCON INC , SHEPARD ALLAN R , CHATTERTON JON E , CLARK ABBOT F , WAX MARTIN B
发明人： SHEPARD ALLAN R , CHATTERTON JON E , CLARK ABBOT F , WAX MARTIN B
IPC分类号： A61K31/713 , C12N15/113
CPC分类号： C12N15/1137 , C12N15/1138 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12Y301/01007 , C12Y306/03009 , C12Y402/01001
摘要： RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; ß1- and ß2 adrenergic receptors; acetylcholinesterase; Na + /K + -ATPase; and Na-K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.
摘要翻译：提供RNA干扰抑制高眼压症目标mRNA表达以降低患有开角型青光眼或高眼压症患者的眼内压升高。眼高血压目标包括碳酸酐酶II，IV和XII; β1-和β2肾上腺素能受体; 乙酰胆碱酯酶; 娜^{+ / K ^{+ -ATP酶; 和Na-K-2Cl协同转运蛋白。通过施用本发明的干扰RNA来治疗眼高压。}}

7. 发明申请

WO2006137052A3 UNIFORMLY CONJUGATED SERINE HYDROLASES 审中-公开
标题翻译：均匀的丝氨酸水解酶
公开(公告)号：WO2006137052A3
公开(公告)日：2007-03-01
申请号：PCT/IL2006000669
申请日：2006-06-08
申请人： ISRAEL STATE , COHEN OFER , KRONMAN CHANOCH , VELAN BARUCH , SHAFFERMAN AVIGDOR
发明人： COHEN OFER , KRONMAN CHANOCH , VELAN BARUCH , SHAFFERMAN AVIGDOR
IPC分类号： G01N33/53
CPC分类号： C12N9/18 , A61K47/60 , C12Y301/01007
摘要： An organophosphate scavenger is provided, with extended residence time in the mammalian circulation, which can be used in preventive and therapeutic treatment of organophosphate poisoning. The scavenger is a uniformly pegylated serine hydrolase, in which a part of lysine residues were replaced with other residues by site-directed mutagenesis. One part of lysine residues in the hydrolase amino acid sequence is selected for the PEG-coupling, and the other part for the replacement, wherein the selection should ensure that the hydrolase surface shows at least one free amino acid for PEG coupling for all possible views obtained by rotating a 3-D model generated for the hydrolase.
摘要翻译：提供了有机磷酸盐清除剂，其在哺乳动物循环中具有延长的停留时间，其可用于预防和治疗有机磷酸盐中毒。清除剂是均匀聚乙二醇化的丝氨酸水解酶，其中一部分赖氨酸残基被其他残基替代，通过定点诱变。选择水解酶氨基酸序列中赖氨酸残基的一部分用于PEG偶联，另一部分用于替换，其中选择应确保水解酶表面显示至少一种用于所有可能视图的PEG偶联的游离氨基酸通过旋转为水解酶产生的3-D模型获得。

8. 发明申请

WO2005077398A2 ARP AS AN INDUCER OF GRANULOCYTOPOIESIS, USES AND METHODS THEREOF 审中-公开
标题翻译： ARP作为颗粒细胞的诱导剂，其用途和方法
公开(公告)号：WO2005077398A2
公开(公告)日：2005-08-25
申请号：PCT/IL2005000185
申请日：2005-02-10
申请人： YISSUM RES DEV CO , MEDICAL RES FUND AT THE TEL AV , SOREQ HERMONA , GRISARU DAN , DEUTSCH VARDA , PERRY CHAVA , PICK MARJORIE
发明人： SOREQ HERMONA , GRISARU DAN , DEUTSCH VARDA , PERRY CHAVA , PICK MARJORIE
IPC分类号： A61K38/46 , A61K38/00
CPC分类号： A61K38/465 , C12Y301/01007
摘要： The present invention describes the use of an AChE-R-derived peptide, also known as ARP, as an inducer of hemopoietic cell differentiation and expansion, specifically for the granulocytic population. In addition, the use of ARP as an inducer of thrombopoietin and pro-inflammatory cytokines is also presented. ARP may further be used in the pre-transplant priming of hematopoietic stem cells. Other uses and methods utilizing ARP are also described herein.
摘要翻译：本发明描述了AChE-R衍生肽（也称为ARP）作为造血细胞分化和扩增的诱导剂，特别是针对粒细胞群体的用途。此外，还提出了使用ARP作为血小板生成素和促炎细胞因子的诱导剂。在造血干细胞的移植前引发中还可以使用ARP。本文还描述了利用ARP的其他用途和方法。

9. 发明申请

WO2004000994A2 NOUVEAU GENE DE L'ACETYLCHOLINESTERASE RESPONSABLE DE LA RESISTANCE AUX INSECTICIDES ET SES APPLICATIONS 审中-公开
标题翻译：新型乙酰胆碱酯酶基因对其耐药性及其应用负有责任
公开(公告)号：WO2004000994A2
公开(公告)日：2003-12-31
申请号：PCT/FR2003/001876
申请日：2003-06-19
申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , UNIVERSITE DE MONTPELLIER 2 , WEILL, Mylène , FORT, Philippe , RAYMOND, Michel , PASTEUR, Nicole
发明人： WEILL, Mylène , FORT, Philippe , RAYMOND, Michel , PASTEUR, Nicole
IPC分类号： C12N
CPC分类号： C12Y301/01007 , C12N9/18
摘要： Nouveau gène de l'acétylcholinestérase ( ace-1 ) responsable de la résistance aux organophosphorés et/ou aux carbamates chez les moustiques, non-homologue au gène de l'acétylcholinestérase de D. melanogaster ( ace-2 ), produits du gène ace-1 (ADNc, protéine AchE1) et leurs applications, notamment pour le criblage de nouveaux insecticides et la détection génétique de la résistance aux organophosphorés et/ou aux carbamates dans les populations de moustiques.
摘要翻译：本发明涉及一种新型乙酰胆碱酯酶基因（ace-1），其负责蚊子中有机磷和/或氨基甲酸酯的抗性，其与黑腹果蝇乙酰胆碱酯酶基因（ace-2），ace-1基因的产物不同源（cDNA，蛋白AchE1）及其应用，特别是用于筛选新型杀虫剂和遗传检测对蚊子群体中有机磷和/或氨基甲酸酯的抗性。

10. 发明申请

WO1998022132A1 A METHOD AND COMPOSITION FOR ENABLING PASSAGE THROUGH THE BLOOD-BRAIN BARRIER 审中-公开
标题翻译：通过血脑屏障通气的方法和组合物
公开(公告)号：WO1998022132A1
公开(公告)日：1998-05-28
申请号：PCT/US1997021696
申请日：1997-11-20
申请人： YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM , KOHN, Kenneth, I. , SOREQ, Hermona , FRIEDMAN, Alon , SEIDMAN, Shlomo , KAUFER, Daniela
发明人： YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM , KOHN, Kenneth, I.
IPC分类号： A61K38/46
CPC分类号： C12Y301/01007 , A61K31/137 , A61K31/138 , A61K31/46 , A61K38/465 , A61K2300/00
摘要： A pharmaceutical composition for facilitating passage of compounds through the blood-brain barrier comprising the agent ACHE-I4 readthrough (SEQ ID No:1) splice variant or the I4 peptide (SEQ ID No:2) and analogues of each thereof and a pharmaceutically acceptable carrier is disclosed. Alternatively, the pharmaceutical composition for facilitating passage of compounds through the blood-brain barrier can comprise the agents adrenaline, atropine, dopamine and/or an adrenergic combination and a pharmaceutically acceptable carrier. The composition can comprise at least two of the agents. The composition of the present invention can optionally include the compound to be transported across the blood-brain barrier. Alternatively, the compound can be co-administered (simultaneously) with the composition or can be administered at some point during the biologically effective period of the action of the composition. The present invention provides a method for administering a compound to the CNS of an animal by subjecting the animal to a stress-mimicking agent or treatment. This agent or treatment facilitates disruption of the blood-brain barrier. During the period that the BBB is opened or disrupted a compound can be administered such that the compound is enabled to pass through the disrupted BBB into the CNS.
摘要翻译：一种用于促进化合物通过包含透明试剂ACHE-I4（SEQ ID No：1）剪接变体或I4肽（SEQ ID No：2）及其各自的类似物的药物组合物和药学上可接受的药物组合物载体被披露。或者，用于促进化合物通过血脑屏障的药物组合物可以包含肾上腺素，阿托品，多巴胺和/或肾上腺素能组合剂和药学上可接受的载体。所述组合物可包含至少两种所述试剂。本发明的组合物可以任选地包括待跨越血脑屏障转运的化合物。或者，化合物可以与组合物共同施用（同时），或者可以在组合物的作用的生物学有效期间的某一点施用。本发明提供了通过使动物经受应激模拟剂或治疗而将化合物给予动物的CNS的方法。该药剂或治疗有助于破坏血脑屏障。在BBB开放或破坏的时期期间，化合物可以被施用使得化合物能够通过破坏的BBB进入CNS。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式